Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
HCP-1803 by Hanmi Pharmaceuticals for Idiopathic (Essential) Hypertension: Likelihood of Approval
HCP-1803 is under clinical development by Hanmi Pharmaceuticals and currently in Phase III for Idiopathic (Essential) Hypertension. According to GlobalData,...